Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...

Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.